CLINICAL STUDY AGREEMENT PROTOCOL: DAL-301 SITE: 18-103I DALCOR PHARMA UK LTD 10- MAY- 2016 VERSION: 1 . 0 COUNTRY : CZECH REPUBLIC SMLOUVA O KLINICKÉ STUDII PROTOKOL: DAL-301 CENTRUM: 18 -103 DALCOR PHARMA UK LTD 10- KVĚTEN- 2016 VERZE: 1 . 0 ZEMĚ:...Clinical Study Agreement • November 7th, 2016
Contract Type FiledNovember 7th, 2016CLINICAL STUDY SMLOUVA O KLINICKÉ AGREEMENT STUDII This clinical study agreement (“Agreement”), effective as of the day last signature under the Agreement (the “Effective Date”), is entered into by and between Medpace, Inc., with its principal office and place of business at 5375 Medpace Way, Cincinnati, Ohio 45227, USA (“Medpace”), identification number in the USA: 1309161, represented by; whose valid authorization for representation with an apostille form is an integral part to this agreement, and Oblastni nemocnice Kladno, a.s., nemocnice Stredoceskeho kraje, with its principal office and place of business at Vančurova 1548, 272 59 Kladno, Czech Republic (“Institution”), ID no.: 27256537, registered in the Companies Register managed by the Municipal Court in Prague under ref. no. 10020, represented by,with his principal office and place of business at Oblastni nemocnice Kladno, a.s., nemocnice Stredoceskeho kraje, Vančurova 1548, 272 59 Kladno, Czech Republic (“Principal Investigato